Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Kuros Biosciences AG

Healthcare US CSBTF

26.0USD
0.00(0%)

Last update at 2026-06-19T20:00:00Z

Day Range

26.0026.00
LowHigh

52 Week Range

26.3342.81
LowHigh

Fundamentals

  • Previous Close 26.00
  • Market Cap1239.48M
  • Volume500
  • P/E Ratio355.00
  • Dividend Yield-%
  • EBITDA11.52M
  • Revenue TTM146.06M
  • Revenue Per Share TTM3.80
  • Gross Profit TTM 127.45M
  • Diluted EPS TTM0.08

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 4.17M -3.34600M -9.77600M -15.99100M -9.55400M
Minority interest - - - - -
Net income 2.12M -3.71600M -13.72700M -14.59500M -7.54100M
Selling general administrative 81.63M 5.08M 3.56M 3.07M 2.58M
Selling and marketing expenses - 36.18M 17.13M 8.08M 4.80M
Gross profit 104.84M 62.03M 28.47M 10.77M 10.07M
Reconciled depreciation 3.37M 2.64M 2.75M 2.83M 2.88M
Ebit 7.33M -3.19700M -9.59000M -11.67400M -8.17100M
Ebitda 10.13M -0.56100M -7.49400M -8.84000M -5.29100M
Depreciation and amortization 2.80M 2.64M 2.10M 2.83M 2.88M
Non operating income net other - - - - -
Operating income 7.33M -4.99500M -13.19200M -13.44600M -8.76700M
Other operating expenses 114.03M 80.55M 46.76M 31.43M 22.58M
Interest expense 0.30M 0.15M 1.75M 4.32M 1.38M
Tax provision 2.55M 0.37M 0.38M -1.39600M -2.01300M
Interest income 0.10M 0.16M 0.40M 1.77M 0.60M
Net interest income -0.37900M 0.47M 2.15M -2.54500M -0.78700M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 2.12M 0.37M 0.38M -1.39600M -2.01300M
Total revenue 121.36M 75.56M 33.56M 17.99M 13.81M
Total operating expenses 97.51M 67.03M 41.66M 24.21M 18.83M
Cost of revenue 16.51M 13.52M 5.09M 7.22M 3.75M
Total other income expense net -3.16401M 1.65M 3.42M -2.54500M -0.78700M
Discontinued operations - - - - -
Net income from continuing ops 2.46M -3.71600M -13.72700M -14.59500M -7.54100M
Net income applicable to common shares - - - -14.59500M -7.54100M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 107.26M 84.54M 71.46M 82.95M 91.34M
Intangible assets 13.15M 14.99M 16.51M 19.41M 22.61M
Earning assets - - - - -
Other current assets 1.07M 2.92M 1.72M 0.54M 0.47M
Total liab 40.30M 25.79M 14.75M 14.09M 14.36M
Total stockholder equity 66.96M 58.75M 56.71M 68.86M 76.98M
Deferred long term liab - - - - -
Other current liab 21.94M 13.46M 11.31M 10.87M 10.12M
Common stock 2.56M 3.79M 3.68M 3.66M 3.28M
Capital stock 3.23M 3.79M 3.68M 3.66M 3.28M
Retained earnings -29.95189M -45.42700M -42.15100M -116.25300M -101.16600M
Other liab - - - - 1.24M
Good will 19.26M 19.43M 24.47M 29.31M 33.39M
Other assets - - - 0.50M -
Cash 15.67M 17.46M 14.21M 24.07M 28.62M
Cash and equivalents - - - - -
Total current liabilities 33.40M 20.90M 13.19M 12.59M 11.29M
Current deferred revenue - - - - -
Net debt -11.73013M -15.66700M -12.06500M -22.15200M -26.47700M
Short term debt 0.52M 0.53M 0.58M 0.42M 0.32M
Short long term debt - - - - -
Short long term debt total 3.94M 1.79M 2.14M 1.91M 2.15M
Other stockholder equity 53.00M 100.39M 73.30M 181.46M 174.86M
Property plant equipment - - - 2.32M 2.45M
Total current assets 65.52M 44.75M 27.19M 31.39M 32.89M
Long term investments - - - - -
Net tangible assets - - - 20.13M 20.98M
Short term investments - - 0.34M - -
Net receivables 31.86M 14.93M 6.41M 3.62M 2.05M
Long term debt - - - - -
Inventory 16.93M 9.44M 4.86M 3.17M 1.76M
Accounts payable 10.95M 6.91M 1.30M 1.30M 0.85M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 41.35M - 21.89M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.26M - -15.85700M - -
Deferred long term asset charges - - - - -
Non current assets total 41.74M 39.78M 44.27M 51.55M 58.44M
Capital lease obligations 1.39M 1.79M 2.14M 1.91M 2.15M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -1.11200M -0.32600M -0.40000M -0.37400M
Change to liabilities - - - 0.00000M 0.00000M
Total cashflows from investing activities -2.02653M -1.11200M -0.32600M -0.40000M -0.37400M
Net borrowings - - - -2.71700M 6.08M
Total cash from financing activities 1.17M 1.34M -0.17100M 3.22M 6.08M
Change to operating activities - - - 1.96M 0.89M
Net income 2.05M -3.92000M -13.34700M -15.99100M -9.55400M
Change in cash -0.06863M 3.81M -9.85700M -4.55800M 0.24M
Begin period cash flow 15.74M 14.21M 24.07M 28.62M 28.39M
End period cash flow 15.67M 18.02M 14.21M 24.07M 28.63M
Total cash from operating activities -0.37805M 3.14M -8.84400M -7.34800M -5.45300M
Issuance of capital stock 2.19M 1.94M 0.50M 6.00M 0.00000M
Depreciation 2.80M 2.64M 2.75M 2.83M 2.88M
Other cashflows from investing activities - -0.01700M -0.00900M - -
Dividends paid - - - - -
Change to inventory -8.25899M -4.64700M -2.47700M -1.58500M -0.34000M
Change to account receivables -18.78879M -7.88500M -4.57200M -1.64100M -0.73700M
Sale purchase of stock - - - - -
Other cashflows from financing activities -0.64560M -0.60400M -0.67200M -2.77600M 6.08M
Change to netincome - - - 5.68M -0.60500M
Capital expenditures 2.03M 1.11M 0.33M 0.40M 0.37M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -13.08144M -3.30500M -3.64900M -1.26600M -0.18700M
Stock based compensation 4.20M 5.13M 0.92M 1.03M 0.39M
Other non cash items 7.86M 2.60M 4.48M 6.04M 1.02M
Free cash flow -2.40458M 2.03M -9.17000M -7.74800M -5.82700M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CSBTF
Kuros Biosciences AG		 - -% 26.00 355.00 - 8.49 10.14 6.31 105.24
ABT
Abbott Laboratories		 -0.58 0.66% 87.83 25.97 17.24 3.57 3.20 3.81 16.75
SYK
Stryker Corporation		 -3.11 1.01% 304.69 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 -0.07 0.09% 79.27 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 -0.96 2.12% 44.33 31.49 17.24 4.41 3.65 4.88 19.19

Reports Covered

Stock Research & News

View All

Profile

Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. It operates through two segments, Medical Devices and Legacy Portfolio. The company provides MagnetOs Granules, an advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold uses to fill bony voids for intervertebral disc space or posterolateral spine; and Attrax, a biphasic calcium phosphate bone grafts that mimic the porous and trabecular structure of cancellous bone, as well as checkmate licensing. The company was incorporated in 2016 and is headquartered in Schlieren, Switzerland.

Kuros Biosciences AG

Wagistrasse 25, Schlieren, Switzerland, 8952

Key Executives

Name Title Year Born
Prof. Joost D. de Bruijn B.S., B.Sc. Ph.D., Ph.D. CEO & Director 1966
Mr. Michael Grau M.B.A., MBA Chief Financial Officer 1962
Mr. Christopher T. Fair Chief Operating Officer 1970
Dr. Katherine Sage D.O., M.S. VP of Medical Affairs & Director of Scientific Affairs NA
Dr. Oliver P. Kronenberg Sr. Legal Counsel NA
Dr. Charlie Campion Sr. VP of Marketing & International Sales NA
Dr. Alistair Irvine Ph.D. Chief Bus. Officer 1969
Dr. Philippe Saudan Ph.D. Chief Devel. Officer 1967
Mr. John Griffin Sr. VP & Pres of US Sales NA
Ms. Florence Barrere de Groot Ph.D. Head of Devel. NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions